BioMarin Closes $850M Notes Offering to Fund Amicus Therapeutics Acquisition

SEC 8-K Filing Notice

Company: BioMarin Pharmaceutical Inc. (BMRN) Filing Date: 2026-02-12 Accession Number: 0001193125-26-048736

Items Filed

Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Summary

BioMarin Pharmaceutical Inc. announced the closing of an $850 million private placement of 5.500% Senior Notes due 2026. The proceeds, along with borrowings from new senior secured term loan facilities totaling $2.8 billion and cash on hand, are earmarked to finance the pending acquisition of Amicus Therapeutics, Inc. and associated fees. BioMarin also anticipates establishing a $600 million senior secured revolving credit facility in connection with the acquisition. The notes are subject to mandatory redemption if the acquisition is not completed by December 19, 2026, or upon the occurrence of certain other events.

The indenture governing the notes includes covenants that restrict BioMarin's ability to incur debt, pay dividends, make investments, and dispose of assets, among other things. These covenants are standard for such debt offerings and are designed to protect the interests of the noteholders. The indenture also outlines events of default that could trigger the acceleration of the notes. This financing package signifies BioMarin's commitment to the Amicus acquisition, a move that could significantly expand its portfolio and market presence in the rare disease space.

This transaction is significant for the pharmaceutical industry as it showcases the continued trend of consolidation and strategic acquisitions. BioMarin's move to acquire Amicus indicates a desire to strengthen its position in the market, potentially leading to increased competition and innovation in the treatment of rare diseases. The financial implications are substantial, with BioMarin taking on significant debt to fund the acquisition, which will impact its balance sheet and future financial performance. Investors will be closely watching the integration of Amicus and the realization of synergies to justify the investment.

Key Takeaways

BioMarin closes $850 million private placement of Senior Notes due 2026.
Proceeds, along with new term loan facilities and cash, will fund the acquisition of Amicus Therapeutics, Inc.
The indenture includes covenants restricting BioMarin's financial activities.
Notes are subject to mandatory redemption if the Amicus acquisition is not completed by December 19, 2026.
BioMarin expects to enter into a $600 million senior secured revolving credit facility in connection with the Acquisition.

Analysis

For investors, this announcement signals a significant strategic move by BioMarin. The acquisition of Amicus could provide access to new markets, technologies, or pipeline assets, potentially driving future growth. However, the substantial debt incurred to finance the acquisition also introduces financial risk. Investors will need to assess the potential synergies and long-term value creation from the acquisition against the increased leverage on BioMarin's balance sheet.

For industry competitors, this acquisition could reshape the competitive landscape, particularly in the rare disease space. The combined entity may have greater market power and resources, potentially impacting pricing, market share, and future deal-making activity. Other companies may need to reassess their strategies and consider similar acquisitions or partnerships to remain competitive. The broader pharmaceutical market will be watching to see if this acquisition proves successful, potentially setting a precedent for future consolidation in the industry.

This post was automatically generated from an SEC 8-K filing.